###begin article-title 0
Angiotensin II Reduces Mitochondrial Content in Skeletal Muscle and Affects Glycemic Control
###end article-title 0
###begin p 1
###xml 43 68 43 68 <email xmlns:xlink="http://www.w3.org/1999/xlink">miyakaz@sc.itc.keio.ac.jp</email>
Corresponding author: Kazutoshi Miyashita, miyakaz@sc.itc.keio.ac.jp
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
OBJECTIVE-Blockade of angiotensin (Ang) II has been shown to prevent new-onset type 2 diabetes. We focused on the effects of AngII on muscle mitochondria, especially on their biogenesis, as an underlining mechanism of type 2 diabetes.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
RESEARCH DESIGN AND METHODS-C2C12 cells and C57bl/6 mice were used to examine roles for AngII in the regulation of muscle mitochondria and to explore whether the effect was mediated by type 1 AngII receptor (AT1R) or type 2 receptor (AT2R).
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 35 37 35 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;8</sup>
###xml 40 42 40 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 494 498 <span type="species:ncbi:10090">mice</span>
###xml 687 691 <span type="species:ncbi:10090">mice</span>
RESULTS-C2C12 cells treated with 10-8-10-6 mol/l AngII reduced the mitochondrial content associated with downregulation of the genes involved in mitochondrial biogenesis. The action of AngII was diminished by blockade of AT2R but not AT1R, whereas overexpression of AT2R augmented the effect. AngII increased mitochondrial ROS and decreased mitochondrial membrane potential, and these effects of AngII were significantly suppressed by blockade of either AT1R or AT2R. Chronic AngII infusion in mice also reduced muscle mitochondrial content in association with increased intramuscular triglyceride and deteriorated glycemic control. The AngII-induced reduction in muscle mitochondria in mice was partially, but significantly, reversed by blockade of either AT1R or AT2R, associated with increased fat oxidation, decreased muscle triglyceride, and improved glucose tolerance. Genes involved in mitochondrial biogenesis were decreased via AT2R but not AT1R under these in vivo conditions.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
CONCLUSIONS-Taken together, these findings imply the novel roles for AngII in the regulation of muscle mitochondria and lipid metabolism. AngII reduces mitochondrial content possibly through AT1R-dependent augmentation of their degradation and AT2R-dependent direct suppression of their biogenesis.
###end p 6
###begin p 7
Published ahead of print at  on 15 December 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 430 431 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 588 589 588 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 808 809 808 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 810 811 810 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 1267 1268 1255 1256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 1269 1270 1257 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 1438 1439 1426 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 1440 1441 1428 1429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 118 126 <span type="species:ncbi:9606">patients</span>
###xml 364 372 <span type="species:ncbi:9606">patients</span>
###xml 420 428 <span type="species:ncbi:9606">patients</span>
###xml 777 785 <span type="species:ncbi:9606">patients</span>
###xml 1207 1215 <span type="species:ncbi:9606">patients</span>
###xml 1257 1265 <span type="species:ncbi:9606">patients</span>
Recent studies have shown that mitochondrial content and function are significantly reduced in the skeletal muscle of patients with type 2 diabetes (1,2). Percutaneous biopsy of vastus lateralis muscle has revealed that subsarcolemmal mitochondria, which are believed to be crucial for glucose transport and fatty acid oxidation, were decreased in type 2 diabetic patients, compared with body weight-matched nondiabetic patients (2). Moreover, reduced mitochondrial content and function in muscle have been also observed in pre-diabetic subjects with a family history of type 2 diabetes (3). Recent microarray analyses have revealed that expression of genes involved in mitochondrial biogenesis and oxidative phosphorylation is coordinately decreased in the skeletal muscle of patients with type 2 diabetes (4,5), for example, peroxisome proliferator-activator receptor gamma co-activator 1alpha (PGC1alpha), a representative transcriptional cofactor for the determination of mitochondrial content and function, and nuclear respiratory factor 1 (NRF1). Furthermore, it has been demonstrated that mitochondrial function evaluated by the rate of ATP synthesis is diminished in the skeletal muscle of diabetic patients and family history-positive pre-diabetic patients (6,7). These findings imply that reduced mitochondrial content in the skeletal muscle is likely to contribute to the development of insulin resistance and type 2 diabetes (8,9).
###end p 9
###begin p 10
###xml 693 695 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 1138 1140 1138 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 1322 1324 1322 1324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 1325 1327 1325 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
Angiotensin (Ang) II, which is composed of eight amino acids, is one of the most important molecules in the renin-angiotensin system. It provokes sodium reabsorption, vasoconstriction, and elevation of blood pressure and also plays a critical role in the physiological regulation of electrolytes and water homeostasis. However, an excess of AngII may lead to tissue damage, such as atherosclerosis, cardiomegaly, and heart and renal failure. AngII is known to exert its biological effects via two functional receptors, type 1 and type 2 angiotensin II receptors (AT1R and AT2R, respectively). To date, most of the known cardiovascular effects of AngII are believed to be attributable to AT1R (10). Recent large-scale clinical trials, including HOPE (Heart Outcomes Prevention Evaluation), LIFE (Losartan Intervention for Endpoint), CHARM (Candesartan in Heart Failure-Assessment of Mortality and Morbidity), and VALUE (Valsartan Antihypertensive Long-term Use Evaluation), have demonstrated that ACE inhibitors or angiotensin II receptor blockers (ARB) prevent new onset of type 2 diabetes via their ability to attenuate AngII signaling (11). As a result of these findings, the significance of AngII for the development of insulin resistance and regulation of energy metabolism has been attracting considerable attention (12-14).
###end p 10
###begin p 11
###xml 472 474 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 475 477 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 685 687 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 896 898 880 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 1208 1210 1192 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 722 727 <span type="species:ncbi:9606">human</span>
###xml 1174 1178 <span type="species:ncbi:10090">mice</span>
It has been demonstrated that AngII provokes insulin resistance in the skeletal muscle through multiple mechanisms. AngII treatment was found to augment reactive oxygen species (ROS) production by stimulating NADPH oxidase in cultured skeletal muscle cells, thus activating multiple redox-sensitive signaling including nuclear factor-kappaB (NF-kappaB) and increasing proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), which impair insulin action (15,16). Inhibition of insulin signaling by AngII at multiple levels including insulin receptor, insulin receptor substrate 1, and phosphatidylinositol 3-kinase has been demonstrated in aortic smooth muscle cells (17). Stimulation of primary cultured human preadipocytes by AngII was found to inhibit differentiation to mature adipocytes, suggesting that the effect of AngII on adipose tissue may influence glycemic control (18). Furthermore, AngII is known to affect other hormones that are related to the regulation of blood pressure, for example, by promoting the release of aldosterone and vasopressin. It has been suggested that changes in catecholamine production by genetic disruption of AT1R in mice may affect glycemic control (19). Diminished tissue perfusion and lowered blood potassium concentration caused by AngII may also be involved in the development of insulin resistance. These findings indicate that various mechanisms are likely to be involved in AngII-induced insulin resistance. However, the effect of AngII on muscle mitochondrial content and subsequent influence on glycemic control has not yet been elucidated.
###end p 11
###begin p 12
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
In a previous study, we showed that cGMP was involved in the regulation of mitochondrial content and function of cultured C2C12 myotubular cells by altering the expressions of the genes related to mitochondrial biogenesis and the antioxidant system (20). Interestingly, cGMP is an intracellular second messenger of the vasodilating substances, natriuretic peptides and nitric oxide, both of which exert antagonistic effects to AngII actions. In the current study, we therefore focused on the effects of AngII on muscle mitochondria, especially on the regulation of their biogenesis, and their relationship with the pathogenesis of glucose intolerance.
###end p 12
###begin title 13
RESEARCH DESIGN AND METHODS
###end title 13
###begin title 14
Cell culture.
###end title 14
###begin p 15
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 239 241 239 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 244 246 244 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;8</sup>
###xml 323 325 323 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 408 410 408 410 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
C2C12 cells (RIKEN BioResource Center, Tsukuba, Japan) were grown in a low-glucose (100 mg/dl) medium, as described previously (20). Cells were fully differentiated, grown to overconfluence, and treated in a 24-well dish with or without 10-6-10-8 mol/l AngII (Sigma, St. Louis, MO); an AT1R blocker, RNH6270 (Olmesartan, 10-5 mol/l, a gift from Daiichi-Sankyo, Tokyo, Japan); or an AT2R blocker, PD123319 (10-5 mol/l; Sigma). Unless indicated otherwise, total DNA, RNA, and proteins were extracted from the cells after 48 h of treatment.
###end p 15
###begin title 16
Transient overexpression of angiotensin receptors in vitro and RNA interference.
###end title 16
###begin p 17
###xml 124 126 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 73 80 <span type="species:ncbi:9031">chicken</span>
###xml 196 201 <span type="species:ncbi:10090">mouse</span>
We constructed angiotensin receptor overexpressing vectors by fusing the chicken beta-actin promoter-driven vector, pCAGGS (21) (a gift from Dr. J. Miyazaki, Osaka University, Japan) with cDNA of mouse AT1R (GenBank accession no. ) or AT2R (). C2C12 cells were transiently transfected with these vectors (0.1 mug/well) using the Lipofectamine LTX Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. We then generated small interfering RNAs (siRNAs) for genetic blockade of AT1R and AT2R. C2C12 cells were transfected with these siRNAs, or scrambled RNA as negative control (Stealth RNAi Negative Control, Invitrogen), by means of a Lipofectamine RNAi Max Reagent (Invitrogen) according to the manufacturer's instructions.
###end p 17
###begin title 18
Quantification of mitochondrial DNA copy number and gene expressions by real-time PCR.
###end title 18
###begin p 19
Quantitative PCR analysis was performed by standard methods. Details of the methods used are provided in the supplemental materials (available in an online-only appendix at (.
###end p 19
###begin title 20
Quantification of mitochondrial mass, ROS production, and membrane potential and ATP content.
###end title 20
###begin p 21
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
Mitochondrial mass, mitochondrial ROS production, and membrane potential of the C2C12 cells were determined, respectively, with the aid of the fluorescent dyes: MitoTracker Green FM, MitoSOX Red, and JC-1 (Molecular Probes, Eugene, OR), following the same procedures as described previously (20). The fluorescent intensity was estimated by a multi-plate reader (Wallac ARVO SX; Perkin Elmer, Wellesley, MA). ATP content of the cells was determined with the chemiluminescence method (ATP bioluminescence Assay Kit HS II; Roche Diagnostics, Basel, Switzerland). For microscopic analysis, C2C12 cells were stained with the fluorescent probes and observed with a confocal microscope (LSM 510; Carl Zeiss, Oberkochen, Germany).
###end p 21
###begin title 22
Quantification of protein levels by Western blotting.
###end title 22
###begin p 23
Western blotting was performed by standard methods. Details of the methods used are provided in the supplemental materials.
###end p 23
###begin title 24
Animal experiments.
###end title 24
###begin p 25
###xml 363 365 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 125 129 <span type="species:ncbi:10090">mice</span>
###xml 498 502 <span type="species:ncbi:10090">mice</span>
###xml 539 543 <span type="species:ncbi:10090">mice</span>
###xml 853 857 <span type="species:ncbi:10090">mice</span>
All animal experiments were performed in accordance with the animal care and use guidelines of Keio University. Male C57bl/6 mice (Nihon Clea, Tokyo, Japan) were maintained under specific pathogen-free conditions, and exogenous AngII was infused at a dose of 0.1 mug/g body wt/day, which is recognized as a subpressor dose that does not influence blood pressure (22). The infusion was carried out via an osmotic mini-pump (Alzet model 1002; Durect, Cupertino, CA) subcutaneously implanted when the mice were 8 weeks old. The AngII-infused mice were treated with or without the AT1R blocker CS-866 (Olmesartan medoxomil, a precursor of olmesartan with a longer effect in vivo than olmesartan, and a gift from Daiichi-Sanko) or the AT2R blocker PD-123319, four times per week by oral administration (10 mg/kg body wt) with a stomach sonde. On day 10, the mice were killed for tissue harvest.
###end p 25
###begin title 26
Glucose tolerance test, indirect calorimetry, and quantification of serum insulin concentration, muscle triglyceride, and enzyme activity of mitochondria.
###end title 26
###begin p 27
###xml 729 731 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 1240 1242 1234 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 36 40 <span type="species:ncbi:10090">mice</span>
###xml 347 351 <span type="species:ncbi:10090">mice</span>
###xml 609 614 <span type="species:ncbi:10090">Mouse</span>
For the glucose tolerance test, the mice were fasted for 8 h and intraperitoneally injected with glucose at 2.0 g/kg body weight. Blood samples were collected from the tail vein, and the blood glucose level was promptly determined with the glucose dehydrogenase method (ACCU-CHEK Aviva, Roche Diagnostics). Oxygen consumption and fat oxidation in mice were determined by means of indirect calorimetry, which was performed for 24 h from 2000 until the next day (ARCO-2000; Arco Systems, Kashiwa, Japan). Serum insulin concentration was determined with an enzyme-linked immunosorbent assay kit (Ultra-Sensitive Mouse Insulin ELISA kit, 200716; Morinaga, Yokohama, Japan). Lipids in quadriceps were extracted with the Folch method (23), and the triglyceride level was determined with a commercially available kit (Triglyceride E-test; Wako, Osaka, Japan). We performed Oil-red-O staining of the muscle, and the method is provided in the supplemental materials. Enzyme activity of the mitochondrial proteins, cytochrome C oxidase (COX) and beta-hydroxyacyl-CoA dehydrogenase (beta-HAD), was determined in the skeletal muscle by a commercially available assay kit (Mitochondria Activity Assay Kit, Bio Chain, Hayward, CA) and a standard method (24), respectively.
###end p 27
###begin title 28
Microarray analysis.
###end title 28
###begin p 29
###xml 60 64 <span type="species:ncbi:10090">mice</span>
Microarray analysis of the skeletal muscle of AngII-infused mice was performed. Details of the methods used are provided in the supplemental materials.
###end p 29
###begin title 30
Statistical analysis.
###end title 30
###begin p 31
Statistical analysis was performed by standard methods. Details of the methods used are provided in the supplemental materials.
###end p 31
###begin title 32
RESULTS
###end title 32
###begin title 33
AngII reduces mitochondrial content in association with increased mitochondrial ROS production and lowers mitochondrial membrane potential in C2C12 cells.
###end title 33
###begin p 34
###xml 169 171 169 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;8</sup>
###xml 174 176 174 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 358 360 358 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 368 369 368 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 376 377 376 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 392 393 392 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 386 393 386 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 634 636 634 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 650 651 650 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 644 651 644 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 747 748 747 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 741 748 741 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 823 824 823 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 817 824 817 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 902 903 902 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 896 903 896 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>C</italic></xref>
To investigate the effect of AngII on mitochondrial content, ROS production, membrane potential, and ATP production, we treated C2C12 myotubular cells with or without 10-8-10-6 mol/l AngII for 48-96 h. Mitochondrial DNA copy number, which is considered to be a surrogate marker of mitochondrial content, showed a dose-dependent reduction (22% reduction at 10-6 mol/l, n = 12, P < 0.01, Fig. 1A) in the AngII-treated groups. The magnitude of reduction was similar for 48 and 96 h of incubation with AngII. Mitochondrial mass, estimated by means of fluorescent staining, also decreased as a result of AngII treatment (9% reduction at 10-6 mol/l, Fig. 1B), in association with a significant increase in mitochondrial ROS (mtROS) (27% increase, Fig. 1B). Mitochondrial membrane potential (mtMP) was lowered (6% decrease, Fig. 1B) by AngII, whereas cellular ATP content was not significantly changed (Fig. 1C).
###end p 34
###begin title 35
Blockade of AT2R but not AT1R reverses mitochondrial reduction in C2C12 cells caused by AngII, whereas blockade of either AT1R or AT2R suppresses AngII-induced changes in mtROS and mtMP.
###end title 35
###begin p 36
###xml 233 235 233 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 272 274 272 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 384 385 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 390 391 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 378 391 378 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic> and <italic>B</italic></xref>
###xml 610 611 610 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 604 611 604 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 957 958 957 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 951 958 951 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 1095 1096 1095 1096 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1089 1096 1089 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic></xref>
To determine the receptor responsible for the effects of AngII on mitochondria, C2C12 cells were subjected to pharmacological and genetic blockade of their receptors. Pharmacological blockade of AngII by the AT1R blocker RNH-6270 (10-5 mol/l) or AT2R blocker PD-123319 (10-5 mol/l) revealed that the decline in mitochondrial content was completely reversed by blockade of AT2R (Fig. 2A and B). Consistent results were obtained by genetic blockade of these receptors by siRNA in that the silencing of AT2R completely reversed the decrease in mitochondrial content, whereas that of AT1R did not affect it (Fig. 2A). We confirmed that the siRNAs achieved >80% reduction in the expression and protein levels of the receptors by using quantitative PCR and Western blotting (data not shown). On the other hand, the increase in mtROS and the decrease in mtMP induced by AngII were partially, but significantly, suppressed by blockade of either AT1R or AT2R (Fig. 2B). Using a confocal microscope, we were able to confirm that the fluorescent probes were distributed specifically in mitochondria (Fig. 2C).
###end p 36
###begin p 37
###xml 264 265 256 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 272 273 264 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 288 289 280 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 282 289 274 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>D</italic></xref>
###xml 407 408 399 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 413 414 405 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 401 414 393 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic> and <italic>B</italic></xref>
###xml 582 583 570 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 576 583 564 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>D</italic></xref>
We also examined the expressions of genes involved in mitochondrial biogenesis (PGC1alpha, NRF1, and mitochondrial transcription factor A [Tfam]) and found that both PGC1alpha and Tfam were decreased in the AngII-treated group (18% and 16% decrease, respectively, n = 12, P < 0.01, Fig. 2D); however, expression of NRF1 was not affected by AngII. Consistent with its effects on mitochondrial content (Fig. 2A and B), AT2R blockade by PD-123319 completely reversed the AII-induced decrease in PGC1alpha and Tfam, but AT1R blockade by RNH-6270 did not affect their expressions (Fig. 2D).
###end p 37
###begin p 38
These results indicate that, under the present experimental condition using C2C12 cells, AT1R-dependent signal pathways have effects on mtROS and mtMP without any change in mitochondrial content, whereas AT2R-dependent pathways influence mitochondrial biogenesis, mtROS, and mtMP. The expression levels of the receptors can thus be expected to determine the effect of AngII on mitochondria.
###end p 38
###begin title 39
Overexpression of AT2R in C2C12 cells augments AngII-induced reduction in mitochondrial biogenesis.
###end title 39
###begin p 40
###xml 125 126 125 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 127 128 127 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 119 128 119 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic>&#8211;<italic>D</italic></xref>
###xml 244 245 244 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 238 245 238 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 374 375 374 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 382 383 382 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 398 399 398 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 392 399 392 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 552 553 548 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 558 559 554 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 546 559 542 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic> and <italic>D</italic></xref>
###xml 674 675 670 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 668 675 664 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>D</italic></xref>
Next, we performed overexpression of the receptors by using the CAG promoter-driven expression vectors in C2C12 cells (Fig. 3A-D). In the AT1R overexpression group, mtDNA was not significantly changed as a result of treatment with AngII (Fig. 3A); however, in the AT2R overexpression group, mtDNA showed a major decrease as the result of treatment with AngII (44% decrease, n = 12, P < 0.01, Fig. 3B). Western blot analysis confirmed that PGC1alpha and Tfam protein levels in the AT2R overexpression group were significantly diminished by AngII (Fig. 3C and D). These results were also compatible with those for their gene expressions under pharmacological blockades (Fig. 2D).
###end p 40
###begin title 41
###xml 37 41 <span type="species:ncbi:10090">mice</span>
Exogenous administration of AngII in mice for 1 week provokes glucose intolerance without changes in body weight or food intake.
###end title 41
###begin p 42
###xml 598 599 598 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 606 607 606 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 622 623 622 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 616 623 616 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 764 765 764 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 772 773 772 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 811 812 811 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 805 812 805 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 970 971 970 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 964 971 964 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 1071 1072 1071 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1077 1078 1077 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1065 1078 1065 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>C</italic> and <italic>D</italic></xref>
###xml 93 97 <span type="species:ncbi:10090">mice</span>
To explore the effects of AngII on muscle mitochondria and glycemic control in vivo, C57bl/6 mice were subjected to chronic infusion of AngII by means of an osmotic pump, combined with the pharmacological blockade of AT1R by CS-866 or of AT2R by PD-123319. We compared the effect on the four groups: control (vehicle implanted), AngII infusion, AngII infusion with AT1R blockade, and AngII infusion with AT2R blockade. In the AngII-treated groups, glucose levels after the glucose challenge were significantly higher than in the control (33% elevation in area under the curve of the glucose level, n = 18, P < 0.01; Fig. 4A), and the AngII-induced change in glycemic control was significantly suppressed by blockade of either AT1R or AT2R (13% or 17% suppression, n = 18, P < 0.05 and 0.01, respectively; Fig. 4A). In the AngII-infused groups, the serum insulin concentrations at 0 and 15 m of the glucose challenge showed a parallel increase with glucose levels (Fig. 4B). There were no significant changes in body weight or food intake in any of the four groups (Fig. 4C and D).
###end p 42
###begin title 43
AngII reduces mitochondrial content and increases triglycerides in the skeletal muscle in both AT1R- and AT2R-dependent manners.
###end title 43
###begin p 44
###xml 143 144 143 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 150 151 150 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 166 167 166 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 160 167 160 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 383 384 383 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 390 391 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 406 407 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 400 407 400 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 653 654 653 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 647 654 647 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 936 937 936 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 930 937 930 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 1270 1271 1264 1265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1264 1271 1258 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>D</italic></xref>
###xml 1401 1402 1395 1396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 1413 1414 1407 1408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1421 1422 1415 1416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1456 1457 1450 1451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 1468 1469 1462 1463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1476 1477 1470 1471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1511 1512 1505 1506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1505 1512 1499 1506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>E</italic></xref>
###xml 1702 1703 1696 1697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1696 1703 1690 1697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>F</italic></xref>
###xml 1821 1822 1815 1816 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1828 1829 1822 1823 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1844 1845 1838 1839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1838 1845 1832 1839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>F</italic></xref>
###xml 2003 2004 1997 1998 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2010 2011 2004 2005 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2026 2027 2020 2021 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 2020 2027 2014 2021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>F</italic></xref>
###xml 72 76 <span type="species:ncbi:10090">mice</span>
We then examined the muscle triglyceride level in the quadriceps of the mice and found that they were higher in the AngII group (78% increase, n = 8, P < 0.01, Fig. 5A) than in the control group. Pharmacological blockade of either AT1R or AT2R caused a significant reduction in the muscle triglyceride level compared with that in the AngII group (26% or 28% reduction, respectively, n = 8, P < 0.05, Fig. 5A). To confirm that lipids were accumulated in the intramyocellular region, we performed Oil-red-O staining and found that AngII infusion increased intramyocellular lipids, and the increase was suppressed by blockade of either AT1R or AT2R (Fig. 5B). We also found that the ceramide content in the muscle was parallel to the triglyceride level (data not shown). The copy number of muscle mitochondrial DNA was reduced in the AngII group, and this change was also significantly diminished by blockade of either AT1R or AT2R (Fig. 5C). Furthermore, COX and beta-HAD activities in the muscle, which represent electron transport and beta-oxidative function of mitochondria, respectively, were significantly reduced in the AngII group, and this change was diminished by blockade of either AT1R or AT2R, in a manner that was parallel to the mitochondrial content (Fig. 5D). These experiments also showed that mtDNA correlated significantly with the area under the curve of the glucose tolerance test (R = -0.285, n = 72, P < 0.01) and muscle triglyceride (R = -0.267, n = 72, P < 0.05) in the quadriceps (Fig. 5E). Respiratory gas analysis was used to estimate oxygen consumption and fat oxidation. Although oxygen consumption measured over 24 h showed no significant changes in the four groups (Fig. 5F), a dramatic decrease in fat oxidation was observed in the AngII-infused group (69% at night and 70% during the day, n = 8, P < 0.05, Fig. 5F), and this change was abrogated by blockade of either AT1R or AT2R and to a greater extent by the AT2R blockade (41% or 46% recovery at night, respectively, n = 8, P < 0.05, Fig. 5F).
###end p 44
###begin title 45
###xml 47 51 <span type="species:ncbi:10090">mice</span>
Blockade of AT2R but not AT1R in AngII-infused mice reverses reduction in expression and protein levels of molecules involved in mitochondrial biogenesis.
###end title 45
###begin p 46
###xml 50 51 50 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 44 51 44 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>D</italic></xref>
###xml 238 239 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 232 239 228 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>A</italic></xref>
###xml 323 324 319 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 329 330 325 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 317 330 313 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>B</italic> and <italic>C</italic></xref>
###xml 606 607 602 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 612 613 608 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 600 613 596 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>B</italic> and <italic>C</italic></xref>
###xml 706 707 702 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 700 707 696 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
Consistent with the result for C2C12 cells (Fig. 2D), AT2R blockade by PD-123319 in AngII-infused mice reversed the reduction in the expression in PGC1alpha and Tfam, but blockade of AT1R by CS-866 did not affect their expressions (Fig. 6A). Western blot analysis and densitometry of the blots confirmed this result (Fig. 6B and C). On the other hand, the AngII-induced reduction in mitochondrial proteins involved in electron transport or fatty acid oxidation (ATP synthase [ATPsyn], COX, and medium-chain fatty acyl-CoA dehydrogenase [MCAD]) were all suppressed by blockade of either AT1R or AT2R (Fig. 6B and C), and the manner of changes in the protein levels was parallel to that seen in mtDNA (Fig. 5B).
###end p 46
###begin p 47
###xml 91 95 <span type="species:ncbi:10090">mice</span>
These results indicate that the AngII-induced reduction in muscle mitochondrial content in mice is caused by AT2R-dependent suppression of mitochondrial biogenesis and also by AT1R-dependent mechanisms that are not directly related to their biogenesis.
###end p 47
###begin title 48
###xml 60 64 <span type="species:ncbi:10090">mice</span>
Microarray analysis of the skeletal muscle of AngII-infused mice.
###end title 48
###begin p 49
Detailed results of microarray analysis are presented in the supplemental materials.
###end p 49
###begin title 50
DISCUSSION
###end title 50
###begin p 51
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
In the study reported here, we found that AngII reduced mitochondrial content in cultured myotubular cells and skeletal muscle of mice. In addition, the AngII-infused mice showed a decrease in fat oxidation that was associated with an increase in intramuscular triglyceride content and impaired glucose tolerance. These findings imply that the cardiovascular hormone AngII, which has been thought previously to act mainly on the cardiovascular system, may have novel roles in the regulation of mitochondria and lipid metabolism in the skeletal muscle.
###end p 51
###begin p 52
###xml 787 791 <span type="species:ncbi:10090">mice</span>
To determine the receptor responsible for the effects of AngII on mitochondrial content, we used pharmacological blockade and RNA interference of the receptors in C2C12 myotubes, which exhibited substantial expressions of both AT1R and AT2R. We found that the decrease in mitochondrial content induced by treatment with AngII for 48 h could be reversed by the pharmacological and genetic blockades of AT2R but not by those of AT1R. Consistent with this finding, AngII decreased the expression levels of PGC1alpha and Tfam, which positively regulate mitochondrial biogenesis, in an AT2R-dependent manner. We further confirmed that this reduction was attributable to AT2R but not to AT1R, by means of overexpression of the receptors in C2C12 cells. In the skeletal muscle of AngII-infused mice, on the other hand, the pharmacological blockade of either AT1R or AT2R partially but significantly reversed the AngII-induced reduction in mitochondrial content. The change in muscle mitochondrial content was parallel to the mitochondrial protein levels of ATPsyn, COX, and MCAD and the enzyme activity of COX and beta-HAD. While still in this in vivo situation, the AngII-induced decrease in expression and protein levels of PGC1alpha and Tfam was prevented by the pharmacological blockade of AT2R but not by that of AT1R. Therefore, the difference in the protein levels under the AT1R blockade was observed between PGC1alpha/Tfam and ATPsyn/COX/MCAD.
###end p 52
###begin p 53
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 759 761 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 833 835 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 364 368 <span type="species:ncbi:10090">mice</span>
These results imply that the in vitro and in vivo regulation of mitochondria by AngII was somewhat different under the present experimental conditions. AngII reduced mitochondrial content predominantly via an AT2R-dependent direct suppression of mitochondrial biogenesis in the cultured myocytes. On the other hand, mitochondrial content in the skeletal muscle in mice appeared to be determined by a complex combination of factors. Cytokines and hormones released from other tissues, ROS production, and nutritional availability are all known to influence mitochondrial DNA copy number in vivo (25). For example, the plasma level of the insulin-sensitizing hormone adiponectin from adipose tissue has been reported to be decreased by AngII infusion via AT1R (26). Because adiponectin has been shown to increase mitochondrial number (27), decreased adiponectin levels via AT1R might affect mitochondria in the in vivo condition. These kinds of mechanisms can explain the difference, which we found in the present study, between the results for AT1R blockade under the in vitro and in vivo experimental conditions.
###end p 53
###begin p 54
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 678 680 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 681 683 681 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
###xml 666 669 <span type="species:ncbi:10116">rat</span>
The finding that the expression and protein levels of molecules involved in mitochondrial biogenesis in skeletal muscle of AngII-infused mice were not modulated by AT1R suggests that AT1R-dependent pathways reduce mitochondrial content by a way other than via the reduction of mitochondrial biogenesis. Therefore, we propose that mitochondrial degradation was involved in the regulation of mitochondrial content in the present study. Mitochondria are degraded in lysosomes by a process known as "mitophagy" (28). Previous studies have shown that AT1R-dependent pathways augment ROS production, which is known to promote mitophagy and reduce mitochondrial content in rat kidney (29,30). Moreover, in our experiments, an AT1R-dependent increase in lysosomes has been observed in AngII-treated C2C12 cells (data not shown). These findings together suggest that the AngII-induced ROS production via AT1R would augment muscle mitophagy and that an AT1R blockade can be expected to protect muscle mitochondria from various insults that lead to mitophagy.
###end p 54
###begin p 55
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 698 700 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 701 703 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 993 995 993 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 1160 1162 1160 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 326 330 <span type="species:ncbi:10090">mice</span>
###xml 448 452 <span type="species:ncbi:10090">mice</span>
Chronic AngII infusion in rodents has been shown to reduce glucose uptake in muscle and provoke insulin resistance (31). Consistent with this finding, our study demonstrated that 1-week exogenous administration of a subpressor dose of AngII with a subcutaneously implanted osmotic pump exacerbated glycemic control in C57bl/6 mice without causing changes in food intake or suppression in insulin secretion. The AngII-induced glucose intolerance in mice was accompanied by a reduction in mitochondrial content and an increase in triglyceride levels in the skeletal muscle. Previous studies have shown a strong relationship between accumulation of intramuscular triglycerides and insulin resistance (32,33). Although triglycerides themselves are thought to be biologically inactive, accumulating muscle triglyceride levels lead to an increase in intramuscular fatty acids, which has been shown to inhibit insulin signaling via phosphorylation of serine residues in insulin receptor substrate 1 (34). Other lipid metabolites, such as long-chain fatty acyl coenzyme A, diacylglycerols, and ceramides, have also been shown to impair muscle insulin signal directly (35).
###end p 55
###begin p 56
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 762 764 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
Muscle triglycerides are believed to increase in association with a reduction in fat oxidation; indeed, a significant relationship between reduced fat oxidation and increased triglyceride levels has been demonstrated by means of percutaneous biopsy of the vastus lateralis muscle in insulin-resistant subjects (36). Moreover, reduced muscle mitochondrial content has been shown to correlate with decreased fat oxidation and insulin resistance in nondiabetic subjects with a family history of type 2 diabetes (37). The fact that PGC1alpha-dependent pathways shift fuel substrates for oxidation from carbohydrates to lipids, in addition to promoting mitochondrial biogenesis, can explain the relationship between mitochondrial content and fat oxidation in muscle (38). These studies point to the importance of mitochondrial content in skeletal muscle as an upstream element in the pathogenesis of intramuscular lipids and insulin resistance.
###end p 56
###begin p 57
###xml 1029 1031 1029 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 1032 1034 1032 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
###xml 660 664 <span type="species:ncbi:10090">mice</span>
The findings in the present study lead us to hypothesize that administration of AngII in mice causes glucose intolerance at least partly by reducing the mitochondrial content in skeletal muscle, which results in reduced fat oxidation and subsequent accumulation of intramuscular lipids. In support of this notion, we identified significant relationships among mitochondrial content in quadriceps on the one hand, and intramuscular triglyceride and the index of glucose intolerance, expressed as area under the curve of glucose levels after glucose challenge, on the other. The results of the in vivo energy expenditure, which showed that the AngII infusion in mice did not change the oxygen consumption, indicate that the reduction in muscle mitochondrial content by AngII was not mediated through changes in chronic physical activity. However, it is possible that AngII first impairs glycemic control and subsequently reduces mitochondrial content, because hyperglycemia itself has been known to decrease mitochondrial content (39,40). Future studies should specifically focus on the time course of the AngII-induced decrease in mitochondrial content and deterioration of glycemic control, as well as their causal relationship.
###end p 57
###begin p 58
###xml 146 150 <span type="species:ncbi:10090">mice</span>
###xml 210 214 <span type="species:ncbi:10090">mice</span>
###xml 655 659 <span type="species:ncbi:10090">mice</span>
To summarize, we have demonstrated that AngII causes a reduction in mitochondrial content in cultured myotubular cells and the skeletal muscle in mice. Exogenous administration of AngII with an osmotic pump in mice provoked glucose intolerance, which is associated with reduced mitochondrial content, decreased fat oxidation, and increased intramuscular triglyceride levels. Putting these findings together suggests that the cardiovascular hormone AngII, which has been thought to act mainly on the cardiovascular system, can also regulate mitochondrial content and lipid metabolism in the skeletal muscle, and thus affect glycemic control. AngII-infused mice are likely to reduce muscle mitochondrial content through both AT1R and AT2R by different mechanisms: through AT1R-dependent augmentation of mitochondrial degradation and AT2R-dependent direct suppression of their biogenesis.
###end p 58
###begin title 59
Supplementary Material
###end title 59
###begin title 60
Online-Only Appendix
###end title 60
###begin p 61
No potential conflicts of interest relevant to this article were reported.
###end p 61
###begin title 62
REFERENCES
###end title 62
###begin p 63
###xml 201 203 201 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;8</sup>
###xml 209 211 209 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 235 236 235 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 316 317 316 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 335 336 335 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 494 495 494 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 503 504 503 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 564 565 564 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 650 651 650 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 662 663 662 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
AngII reduces mitochondrial content in association with an increase in mitochondrial ROS production in C2C12 cells. C2C12 cells were incubated with or without AngII (at the concentrations indicated: 10-8 or 10-6 mol/l) for 48 or 96 h. A: Mitochondrial DNA copy number (mtDNA) estimated by quantitative PCR analysis (n = 12 per group). B: Mitochondrial density (Mt), mitochondrial ROS production (mtROS), and mitochondrial membrane potential (mtMP) estimated with the aid of fluorescent probes (n = 12). C: ATP content determined with the chemiluminescence method (n = 12). The values were standardized to those for the control (no AngII treatment). *P < 0.05, **P < 0.01 vs. control.
###end p 63
###begin p 64
###xml 170 172 170 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 219 221 219 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 295 297 295 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 315 316 315 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 317 318 317 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 422 423 422 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 426 427 426 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 507 508 507 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 526 527 526 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 685 686 685 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 694 695 694 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 934 935 933 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 995 996 994 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1060 1061 1059 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1072 1073 1071 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1095 1096 1094 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1107 1108 1106 1107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Pharmacological blockade or targeted silencing of AT2R but not AT1R in C2C12 cells recovers mitochondrial biogenesis reduced by AngII. The AT1R blocker, RNH-6270 (RNH, 10-5 mol/l), or the AT2R blocker, PD-123319 (PD, 10-5 mol/l), was added to C2C12 cells previous to the treatment with AngII (10-6 mol/l) for 48 h (A-D). Targeted disruption of AT1R (1Ri) or AT2R (2Ri) by small interfering RNA (siRNA) was also performed (A). A: Mitochondrial DNA copy number (mtDNA) estimated by quantitative PCR analysis (n = 12 per group). B: Mitochondrial density (Mt), mitochondrial ROS production (mtROS), and mitochondrial membrane potential (mtMP) estimated with the aid of fluorescent probes (n = 12). C: Microscopic analysis of the cells. C2C12 cells were stained with MitoTracker Green (green, a probe for mitochondria) or MitoSOX Red (red, a probe for mitochondria-derived ROS) and observed with a confocal microscope. Scale bar: 100 mum. D: Expression of genes involved in mitochondrial biogenesis (n = 12). The values were standardized to those for the control. *P < 0.05, **P < 0.01 vs. control. #P < 0.05, ##P < 0.01 vs. the AngII-treated group. (Please see  for a high-quality digital representation of this figure.)
###end p 64
###begin p 65
###xml 256 258 256 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 276 277 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 278 279 278 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 395 396 395 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 407 408 407 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 411 412 411 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 430 431 430 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 526 527 522 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 675 676 664 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 739 740 728 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 751 752 740 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Overexpression of AT2R in C2C12 cells augments AngII-induced reduction in mitochondrial biogenesis. Angiotensin II receptors (AT1R or AT2R) were overexpressed in C2C12 cells by CAG promoter-driven expression vectors previous to the treatment with AngII (10-6 mol/l) for 48 h (A-D). Mitochondrial DNA copy number (mtDNA) estimated by quantitative PCR analysis in C2C12 cells overexpressing AT1R (A) or AT2R (B) (n = 12 per group). C: Western blots of proteins that are related to mitochondrial biogenesis (PGC1alpha and Tfam). D: Densitometry of the Western blots. The density of the blots for PGC-1alpha and Tfam was normalized by that for the internal control (beta-actin) (n = 8). The values were standardized to those for the control. *P < 0.05, **P < 0.01 vs. control.
###end p 65
###begin p 66
###xml 394 395 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 396 397 395 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 400 401 399 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 581 582 580 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 600 601 599 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 681 682 680 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 775 776 774 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 822 823 821 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 834 835 833 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 857 858 856 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 869 870 868 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 37 41 <span type="species:ncbi:10090">mice</span>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
###xml 699 703 <span type="species:ncbi:10090">mice</span>
###xml 793 797 <span type="species:ncbi:10090">mice</span>
Exogenous administration of AngII in mice for 1 week provokes glucose intolerance without changes in body weight or food intake. The 8-week-old male C57bl/6 mice were treated with a subpressor dose (0.1 mug/g body wt/day) of AngII or PBS (vehicle) by means of a subcutaneously implanted osmotic pump. The AT1R blocker, CS-866 (CS), or the AT2R blocker, PD-123319 (PD), was orally administered (A-D). A: Blood glucose levels (mg/dl) at 0, 15, 30, 60, and 120 min after intraperitoneal injection of 2.0 g/kg body wt glucose and area under the curve of the glucose level (% vehicle) (n = 18 per group). B: Serum insulin levels during glucose tolerance test at 0 and 15 min (0m, 15m). C: Body weight of mice before and 1 week after the implantation of osmotic pumps (pre, post). D: Food intake of mice during the experiment. *P < 0.05, **P < 0.01 vs. control; #P < 0.05, ##P < 0.01 vs. the AngII-treated group.
###end p 66
###begin p 67
###xml 141 142 141 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 222 223 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 240 241 240 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 390 391 389 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 457 458 456 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 466 467 465 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 609 610 602 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 618 619 611 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 827 828 820 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 902 903 895 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 914 915 907 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 937 938 930 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
AngII reduces mitochondrial content and increases triglyceride (TG) content in the skeletal muscle in both AT1R- and AT2R-dependent manners. A: Muscle triglyceride content (muscle triglyceride) measured in the quadriceps (n = 8 per group). B: Histological analysis of AngII-induced lipid accumulation in muscle by Oil-red-O staining. Neutral lipids were stained in red. Scale bar: 100 mum. C: mtDNA of the quadriceps estimated by quantitative PCR analysis (n = 12). D: Enzyme activity in the muscle of the mitochondrial proteins, cytochrome C oxidase (COX), and beta-hydroxyacyl-CoA dehydrogenase (beta-HAD) (n = 12). E: The relationship between area under the curve of the glucose levels in the glucose tolerance test and mtDNA, or between muscle triglyceride and mtDNA. Symbols were distinguished according to the treatment. F: Oxygen consumption and fat oxidation analyzed by indirect calorimetry. *P < 0.05, **P < 0.01 vs. control; #P < 0.05 vs. the AngII-treated group. (Please see  for a high-quality digital representation of this figure.)
###end p 67
###begin p 68
###xml 155 156 155 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 251 252 251 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 270 271 270 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 430 431 423 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 554 555 544 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 619 620 609 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 642 643 632 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 654 655 644 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 245 249 <span type="species:ncbi:10090">mice</span>
Blockade of AT2R but not AT1R in AngII-infused mice reverses reduction in expression and protein levels of molecules involved in mitochondrial biogenesis. A: Expression of genes involved in mitochondrial biogenesis in the skeletal muscle of the mice (n = 12 per group). B: Western blots of proteins that are related to mitochondrial biogenesis (PGC1alpha and Tfam), electron transport (ATPsyn and COX), and beta-oxidation (MCAD). C: Densitometry of the Western blots. The density of the blot was normalized by that for the internal control (beta-actin) (n = 8). The values were standardized to those for the control. **P < 0.01 vs. control; #P < 0.05, ##P < 0.01 vs. the AngII-treated group.
###end p 68

